MX169322B - Formulacion farmaceutica de liberacion prolongada - Google Patents

Formulacion farmaceutica de liberacion prolongada

Info

Publication number
MX169322B
MX169322B MX014267A MX1426788A MX169322B MX 169322 B MX169322 B MX 169322B MX 014267 A MX014267 A MX 014267A MX 1426788 A MX1426788 A MX 1426788A MX 169322 B MX169322 B MX 169322B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
prolonged release
active ingredient
micrograins
eudragit
Prior art date
Application number
MX014267A
Other languages
English (en)
Inventor
Gareth Lewis
Howard Stevens
Maryvonne Chariot
Francoise Arnold
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of MX169322B publication Critical patent/MX169322B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a formulación farmaceutica de liberación prolongada que permite la disolución controlada del principio activo, independientemente del pH, caracterizada en que está constituida por microgranos que contienen el principio activo envuelto con una mezcla de etilcelulosa y de Eudragit RS.
MX014267A 1987-12-21 1988-12-20 Formulacion farmaceutica de liberacion prolongada MX169322B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8717855A FR2624732B1 (fr) 1987-12-21 1987-12-21 Formulation pharmaceutique a liberation prolongee

Publications (1)

Publication Number Publication Date
MX169322B true MX169322B (es) 1993-06-29

Family

ID=9358116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX014267A MX169322B (es) 1987-12-21 1988-12-20 Formulacion farmaceutica de liberacion prolongada

Country Status (23)

Country Link
US (1) US5112621A (es)
EP (1) EP0322277B1 (es)
JP (1) JPH082782B2 (es)
KR (1) KR960009650B1 (es)
AR (1) AR243378A1 (es)
AT (1) ATE71837T1 (es)
AU (1) AU609916B2 (es)
CA (1) CA1332567C (es)
DE (1) DE3868037D1 (es)
DK (1) DK172370B1 (es)
ES (1) ES2051881T3 (es)
FI (1) FI97445C (es)
FR (1) FR2624732B1 (es)
GR (1) GR3003826T3 (es)
HU (1) HU199685B (es)
IE (1) IE60313B1 (es)
IL (1) IL88736A (es)
IT (1) IT8723196A0 (es)
MX (1) MX169322B (es)
NO (1) NO179357C (es)
NZ (1) NZ227412A (es)
PT (1) PT89276B (es)
ZA (1) ZA889495B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145418A (ja) * 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
GB2258613B (en) * 1991-08-12 1996-01-10 Euro Celtique Sa Pharmaceutical diltiazem formulation
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
ATE217789T1 (de) * 1992-06-04 2002-06-15 Smithkline Beecham Corp Angenehm schmeckende pharmazeutische zusammensetzungen
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3264722B2 (ja) * 1993-02-25 2002-03-11 第一製薬株式会社 カプセル製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
FR2742660B1 (fr) 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US6663896B1 (en) 2001-08-01 2003-12-16 Alvin S. Blum Delayed release aspirin for vascular obstruction prophylaxis
KR100407519B1 (ko) * 2001-08-31 2003-12-18 부광약품 주식회사 건조황산제일철과 방출조절제로서 엘-글루타민을 함유하는서방성 정제 및 그의 제조방법
KR100446818B1 (ko) * 2001-11-06 2004-09-01 김재윤 질산 이소소르비드 서방성 펠렛 제형
US20050095292A1 (en) * 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
KR100775957B1 (ko) * 2006-02-07 2007-11-13 경상대학교산학협력단 애기장대 유래의 개화시기를 조절 단백질 ｃｏ의 돌연변이단백질, 상기 단백질을 이용한 식물의 개화시기 조절전사인자의 분리방법 및 식물의 개화시기 조절방법
CN100442981C (zh) * 2006-11-09 2008-12-17 广东省昆虫研究所 一种德国小蠊毒饵
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
CA2992211C (en) 2013-03-14 2021-09-21 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR101639163B1 (ko) * 2015-07-08 2016-07-22 울산대학교 산학협력단 저전송 영상 정보 및 센싱 정보 송수신 장치 및 이의 동작 방법
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
JPS625915A (ja) * 1985-07-03 1987-01-12 Nippon Iyakuhin Kogyo Kk 塩酸ジルチアゼム徐放性製剤及びその製法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Also Published As

Publication number Publication date
EP0322277A1 (fr) 1989-06-28
EP0322277B1 (fr) 1992-01-22
PT89276A (pt) 1989-12-29
HU199685B (en) 1990-03-28
NO179357B (no) 1996-06-17
DE3868037D1 (de) 1992-03-05
HUT49290A (en) 1989-09-28
IE883810L (en) 1989-06-21
NO885641D0 (no) 1988-12-20
GR3003826T3 (es) 1993-03-16
FI97445B (fi) 1996-09-13
ZA889495B (en) 1989-09-27
IL88736A (en) 1992-11-15
NO179357C (no) 1996-09-25
JPH082782B2 (ja) 1996-01-17
ATE71837T1 (de) 1992-02-15
IE60313B1 (en) 1994-06-29
FI885884A0 (fi) 1988-12-20
FR2624732B1 (fr) 1991-02-15
JPH02202A (ja) 1990-01-05
DK708088A (da) 1989-06-29
NZ227412A (en) 1989-12-21
IT8723196A0 (it) 1987-12-23
FI885884L (fi) 1989-06-22
CA1332567C (en) 1994-10-18
KR960009650B1 (en) 1996-07-23
PT89276B (pt) 1993-12-31
AR243378A1 (es) 1993-08-31
FR2624732A1 (fr) 1989-06-23
ES2051881T3 (es) 1994-07-01
FI97445C (fi) 1996-12-27
IL88736A0 (en) 1989-07-31
AU2707788A (en) 1989-06-22
KR890009380A (ko) 1989-08-01
US5112621A (en) 1992-05-12
DK708088D0 (da) 1988-12-20
AU609916B2 (en) 1991-05-09
DK172370B1 (da) 1998-04-27
NO885641L (no) 1989-06-22

Similar Documents

Publication Publication Date Title
MX169322B (es) Formulacion farmaceutica de liberacion prolongada
NO912001L (no) Buccal tablett med hurtig utlevering.
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
ES2042541T3 (es) Un procedimiento de preparacion de una formulacion farmaceutica de liberacion retardada que contiene goma de xantano.
DE3778223D1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
ES2159591T3 (es) Composicion de liberacion controlada.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
ES2115638T3 (es) Composicion tiroactiva de liberacion controlada.
ES2058420T3 (es) Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos.
ES2060593T3 (es) Sistema de aporte de farmacos.
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
AR240250A1 (es) Procedimiento para la preparacion de una nueva formualcion farmaceutica oral que contiene omeprazol como ingrediente activo.
GR3007202T3 (es)
PT954314E (pt) Formas de dosagem farmaceutica para melhorar a disfuncao erectil masculina
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
ATE87471T1 (de) Eine fluessige verabreichungsform fuer orale verabreichung einer pharmazeutischen substanz.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DK98088A (da) Farmaceutisk formulering med forsinket frigivelse af den aktive bestanddel
FI94094B (fi) Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle
IL37313A0 (en) Selective herbicidal compositions comprising an aromatic amine or a thiophosphoric acid ester together with another active ingredient,their preparation and their use
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
MX9305143A (es) Composiciones nutritivas o medicamentos a base de quitosana, para la administracion de los rumiantes y procedimiento para su preparacion.